A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa

The global increase in multidrug resistant (MDR) bacteria has led to phage therapy being refocused upon. A novel endolysin, LysPA26, containing a lysozyme-like domain, was screened against <i>Pseudomonas aeruginosa</i> in this study. It had activity against MDR <i>P. aeruginosa</i> without pretreatment with an outer-membrane permeabilizer. LysPA26 could kill up to 4 log units <i>P. aeruginosa</i> in 30 min. In addition, temperature and pH effect assays revealed that LysPA26 had good stability over a broad range of pH and temperatures. Moreover, LysPA26 could kill other Gram-negative bacteria, such as <i>Klebsiella pneumonia, Acinetobacter baumannii</i> and <i>Escherichia coli</i>, but not Gram-positive bacteria. Furthermore, LysPA26 could eliminate <i>P. aeruginosa</i> in biofilm formation. Our current results show that LysPA26 is a new and promising antimicrobial agent for the combat of Gram-negative pathogens.